Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
相关临床试验
27
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
进行中（未招募）
6
22.2%
已完成
13
48.1%
尚未招募
2
7.4%
招募中
5
18.5%
终止
1
3.7%
暂无批准数据
- The article is a Seeking Alpha analyst opinion piece discussing Annexon (NASDAQ: ANNX) as a speculative biotech investment opportunity. - The author discloses a beneficial long position in Annexon shares and expresses personal opinions about the company's portfolio fit. - No clinical trial data, regulatory milestones, or specific drug development updates are presented in the source material. - The content consists solely of financial disclosure statements and does not contain substantive pharmaceutical R&D news suitable for clinical reporting.
- Annexon has submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart, potentially the first targeted fast-acting therapy for Guillain-Barré syndrome. - The submission is based on comprehensive Phase 3 data showing tanruprubart rapidly stops neuroinflammation and enables faster, more complete patient recovery from this life-threatening disease. - Guillain-Barré syndrome affects at least 150,000 people worldwide annually with no currently approved treatments, representing a significant unmet medical need. - A Biologics License Application submission to the FDA is planned for 2026, with ongoing studies designed to support broad pediatric and adult patient labeling.
- Eight biotech companies raised a record $3.5 billion in a single night following the American Society of Hematology conference, marking the busiest day ever in biotech fundraising. - Terns Pharmaceutical led the surge with a $650 million offering after presenting Phase I leukemia trial data showing 64% response rates, with potential peak sales projected at $2.5 billion. - Fulcrum Therapeutics raised $175 million following positive Phase Ib results for its sickle cell disease treatment in expectant mothers, demonstrating meaningful increases in fetal hemoglobin levels. - The fundraising wave reflects strong biotech sector performance with the NYSE Arca Biotechnology Index up 27% year-to-date, driven by positive trial results and increased M&A activity.
- Over 20 pharmaceutical and biotech companies are actively developing more than 20 therapeutic candidates for Huntington's disease at various clinical and preclinical stages. - PTC Therapeutics received FDA Fast Track designation for PTC518 in September 2024 and signed a licensing agreement with Novartis worth up to $2.9 billion for its development. - The FDA expanded valbenazine (Ingrezza) indication in August 2023 to include Huntington's disease-associated chorea, making it the only approved selective VMAT2 inhibitor for this condition. - Key pipeline candidates include RG6042 (Hoffmann-La Roche), PTC518 (PTC Therapeutics), and ALN-HTT02 (Alnylam Pharmaceuticals), targeting different mechanisms to reduce huntingtin protein production.
- The European Medicines Agency has selected Annexon's vonaprument to participate in its new Product Development Coordinator pilot program, providing enhanced regulatory support for the potential first-in-class dry AMD treatment. - Vonaprument is the only investigational therapy in geographic atrophy to demonstrate significant vision preservation on best corrected visual acuity and low luminance visual acuity endpoints in clinical trials. - The Phase 3 ARCHER II trial has completed enrollment with over 630 patients, with topline data expected in the second half of 2026 for this potential breakthrough therapy. - Geographic atrophy affects approximately one million people in the United States and eight million globally, with no currently approved therapies shown to significantly prevent vision loss.
- The complement-based therapeutics field is experiencing significant growth following recent FDA approvals, including Novartis' alternative complement inhibitor for PNH and SYFOVRE approval. - Multiple complement inhibitors are advancing through clinical trials across diverse therapeutic areas including nephrology, ophthalmology, neurodegeneration, and inflammation. - Industry focus is expanding beyond rare diseases to larger patient populations, with companies exploring combination therapies and indication expansion strategies. - The 8th Annual Complement-Based Drug Development Summit will convene 100+ industry leaders to address key challenges in complement pathway targeting and clinical trial design.
- DelveInsight's 2025 pipeline analysis reveals over 20 active companies developing more than 20 pipeline drugs for Huntington's disease, including gene-targeting and disease-modifying therapies. - Major regulatory milestones include FDA breakthrough therapy designation for AMT-130 in April 2025 and Novartis's $1 billion upfront licensing deal with PTC Therapeutics for PTC518. - The treatment landscape features diverse therapeutic approaches including RNA splicing modulators, HDAC inhibitors, and complement inhibitors across various clinical trial phases. - Current treatment options remain limited to two FDA-approved medications, Austedo and Xenazine, which only manage chorea symptoms rather than modify disease progression.
- Phase 2 ARCHER trial data demonstrates ANX007's ability to preserve vision in patients with dry AMD and geographic atrophy, showing significant protection across multiple visual function measures. - ANX007, a first-in-kind C1q inhibitor, has received Fast Track designation from the FDA and is the first GA treatment to receive PRIME designation in the EU, highlighting its potential therapeutic advantage. - The global Phase 3 ARCHER II trial is currently enrolling approximately 630 patients, with topline data expected in the second half of 2026.
- Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment. - Enrollment in the Phase 3 ARCHER II trial for ANX007 in geographic atrophy (GA) is expected to be completed in the latter half of 2025. - Clinical proof-of-concept data for ANX1502, an oral C1s inhibitor targeting autoimmune conditions, is anticipated in the first quarter of 2025. - Annexon's current cash reserves are projected to sustain operations into the second half of 2026, supporting the achievement of critical developmental milestones.
- Annexon anticipates submitting a Biologics License Application (BLA) for ANX005 in the first half of 2025, marking it as a potential first targeted therapy for Guillain-Barré Syndrome. - Enrollment in the Phase 3 ARCHER II trial for ANX007, a neuroprotective therapy for Geographic Atrophy, is expected to be completed in the second half of 2025. - Clinical proof-of-concept data for ANX1502, the first oral C1s inhibitor being developed for Cold Agglutinin Disease, is anticipated in the first quarter of 2025.
